TORONTO, March 4, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Company is scheduled to present at the following two upcoming conferences.
- 26 th Annual Roth Conference on March 10, 2014 at 11:00am (PDT) at The Ritz-Carlton in Dana Point, CA.
- 13 th Annual Needham Healthcare Conference on April 8, 2014 at 3:00pm (EDT) at The Westin Grand Central Hotel, New York, NY.
The presentations will be webcast live and may be accessed through the Investor Relations' Events and Presentations section on Intellipharmaceutics' website at www.intellipharmaceutics.com .
Please go to the website at least 15 minutes prior to the applicable event to register, download and install any necessary audio/video software. An archived replay will also be available for 90 days following each live presentation.About Intellipharmaceutics Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (our dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths which recently received final FDA approval) and product candidates in various stages of development, including Abbreviated New Drug Applications ("ANDAs") filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain. Intellipharmaceutics also has New Drug Application 505(b)(2) product candidates in its development pipeline. These include Rexista™ oxycodone, an abuse-deterrent oxycodone, based on its proprietary nPODDDS™ novel Point Of Divergence Drug Delivery System, and Regabatin™ XR pregabalin extended-release capsules.